Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureAbstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Antibody-drug conjugates in breast cancer: from mechanism to revolutionizing clinical practice
10.1186/s12943-026-02711-9 · 2026
Immunotherapy resistance in triple-negative breast Cancer: mechanisms and emerging therapeutic strategies
10.1016/j.canlet.2026.218690 · 2026
Breast cancer
10.1038/s41572-019-0111-2 · 2019
Breast Cancer treatment: a review
10.1001/jama.2018.19323 · 2019
Heterogeneity in breast cancer
10.1172/jci60534 · 2011
Molecular portraits of human breast tumours
10.1038/35021093 · 2000
Fundamentals of cancer metabolism
10.1126/sciadv.1600200 · 2016
Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate
10.1016/j.ccr.2012.02.014 · 2012
Metabolic reprogramming and cancer progression
10.1126/science.aaw5473 · 2020
Understanding the Warburg effect: the metabolic requirements of cell proliferation
10.1126/science.1160809 · 2009
Nitric oxide-driven Warburg reprogramming at the NOS2-COX2 axis: an integrative engine of cancer hallmarks
10.1016/j.redox.2026.104245 · 2026
The hallmarks of cancer metabolism: still emerging
10.1016/j.cmet.2022.01.007 · 2022
Metabolic reprogramming in breast cancer: pathways driving progression, drug resistance, and emerging therapeutics
10.1016/j.bbcan.2025.189396 · 2025
Targeting mitochondria metabolism for cancer therapy
10.1038/nchembio.1712 · 2015
From Krebs to clinic: glutamine metabolism to cancer therapy
10.1038/nrc.2016.71 · 2016
The multifaceted roles of fatty acid synthesis in cancer
10.1038/nrc.2016.89 · 2016
Cancer metabolism: fatty acid oxidation in the limelight
10.1038/nrc3483 · 2013
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer
10.1038/nature10350 · 2011
Metastatic breast cancer cells are metabolically reprogrammed to maintain redox homeostasis during metastasis
10.1016/j.redox.2024.103276 · 2024
Metabolic interactions in the tumor microenvironment
10.1016/j.tcb.2017.06.003 · 2017
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation
10.1016/j.cmet.2007.10.002 · 2008
Aerobic glycolysis: meeting the metabolic requirements of cell proliferation
10.1146/annurev-cellbio-092910-154237 · 2011
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
10.1038/s41568-019-0216-7 · 2020
Epigenetic switch-induced viral mimicry evasion in chemotherapy-resistant breast Cancer
10.1158/2159-8290.cd-19-1493 · 2020
Metabolic plasticity as a determinant of tumor growth and metastasis
10.1158/0008-5472.can-16-0266 · 2016
A single-cell and spatially resolved atlas of human breast cancers
10.1038/s41588-021-00911-1 · 2021
A single-cell atlas of the tumor and immune ecosystem of human breast Cancer
10.1016/j.cell.2019.03.005 · 2019
Metabolic phenotypes in triple-negative breast cancer
10.1007/s13277-013-0707-1 · 2013
Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics
2024
Cancer stem cell metabolism
10.1186/s13058-016-0712-6 · 2016
Targeting cancer stem cell redox metabolism to enhance therapy responses
10.1016/j.semradonc.2018.10.003 · 2019
Toward minimal residual disease-directed therapy in melanoma
10.1016/j.cell.2018.06.025 · 2018
The plasticity of pancreatic cancer metabolism in tumor progression and therapeutic resistance
10.1016/j.bbcan.2018.04.011 · 2018
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations
10.1016/j.cell.2010.02.027 · 2010
Cycling cancer persister cells arise from lineages with distinct programs
10.1038/s41586-021-03796-6 · 2021
Epigenetic reprogramming of Cancer-associated fibroblasts deregulates glucose metabolism and facilitates progression of breast Cancer
10.1016/j.celrep.2020.107701 · 2020
Lactate-activated macrophages induced aerobic glycolysis and epithelial-mesenchymal transition in breast cancer by regulation of CCL5-CCR5 axis: a positive metabolic feedback loop
10.18632/oncotarget.22786 · 2017
Interaction between CD36 and FABP4 modulates adipocyte-induced fatty acid import and metabolism in breast cancer
10.1038/s41523-021-00324-7 · 2021
Inhibitory effect of tumor cell-derived lactic acid on human T cells
10.1182/blood-2006-07-035972 · 2007
LDHA-associated lactic acid production blunts tumor Immunosurveillance by T and NK cells
10.1016/j.cmet.2016.08.011 · 2016
Drug resistance in cancer: molecular mechanisms and emerging treatment strategies
10.1186/s43556-025-00352-w · doi-reference
OXPHOS-targeting drugs in oncology: new perspectives
10.1080/14728222.2023.2261631 · doi-reference
Transcriptional diversity and bioenergetic shift in human breast cancer metastasis revealed by single-cell RNA sequencing
10.1038/s41556-020-0477-0 · doi-reference
IKKbeta promotes metabolic adaptation to glutamine deprivation via phosphorylation and inhibition of PFKFB3
10.1101/gad.287235.116 · doi-reference
Adaptability of lung and liver metastatic breast cancer cells to glucose
10.1186/s12935-025-04006-3 · doi-reference
Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: mechanism of cell death
10.1038/sj.bjc.6600547 · doi-reference
HSP90AA1-VDAC1 interaction contributes to breast cancer progression and doxorubicin resistance through PI3K/AKT signaling
10.1186/s13058-026-02225-8 · doi-reference
18F-FDG PET/CT for monitoring of treatment response in breast cancer
10.2967/jnumed.115.157875 · doi-reference
Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer
10.1186/s13045-022-01236-0 · doi-reference
Glycosylated extracellular matrix drives immune suppression by modulating macrophage-T cell crosstalk in triple-negative breast cancer
10.1038/s41467-026-73467-5 · doi-reference
Bulk and single-cell transcriptome profiling reveal the metabolic heterogeneity in human breast cancers
10.1016/j.ymthe.2021.03.003 · doi-reference
Targeting the cancer metabolism-immunity interface: update and perspectives
10.1186/s40164-026-00776-2 · doi-reference
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study
10.1016/s1470-2045(19)30274-8 · doi-reference
Abstract PS5–01-16: Phase II Trial of the FASN Inhibitor, Denifanstat (TVB-2640), Plus Trastuzumab in Combination with Paclitaxel or Endocrine Therapy (ET) in Patients with HER2+ Metastatic Breast Cancer (MBC) Resistant to Trastuzumab
10.1158/1557-3265.sabcs25-ps5-01-16 · doi-reference
First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors
10.1016/j.eclinm.2021.100797 · doi-reference
Targeting lipid metabolism enzymes in breast Cancer: mechanistic basis and therapeutic vulnerabilities
10.1016/j.ejphar.2026.179131 · doi-reference
Glutamine synthetase shields triple-negative breast cancer cells from ferroptosis in metastasis triggered by glutamine deprivation
10.1186/s13058-025-02115-5 · doi-reference
Complex I drives glutamine-dependent TCA cycle to support viability of MYC(high) breast cancer cells
10.1016/j.celrep.2026.117629 · doi-reference
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
10.1038/s41591-022-02103-8 · doi-reference
Metabolic targeting of oxidative phosphorylation enhances Chemosensitivity in triple-negative breast Cancer via a synergistic nanomedicine
10.7150/thno.116250 · doi-reference
Effect of metformin vs placebo on invasive disease-free survival in patients with breast Cancer: the MA.32 randomized clinical trial
10.1001/jama.2022.6147 · doi-reference
Metformin selectively targets cancer stem cells
10.1158/0008-5472.can-09-2994 · doi-reference
Role of AMP-activated protein kinase in mechanism of metformin action
10.1172/jci13505 · doi-reference
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain
10.1042/bj3480607 · doi-reference
Syrosingopine enhances immune checkpoint blockade efficacy by inhibition of MCTs and metabolic reprogramming in triple-negative breast cancer
10.1016/j.bbadis.2026.168308 · doi-reference
Understanding tumor heterogeneity: implications for precision oncology and therapeutic strategies
10.1016/j.bbcan.2026.189617 · doi-reference
Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer
10.1158/1078-0432.ccr-13-2270 · doi-reference
Deletion of lactate dehydrogenase-a in myeloid cells triggers antitumor immunity
10.1158/0008-5472.can-16-2938 · doi-reference
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
10.1038/s41467-020-18020-8 · doi-reference
Identification and optimization of the first highly selective GLUT1 inhibitor BAY-876
10.1002/cmdc.201600276 · doi-reference
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies
10.1002/pros.21172 · doi-reference
Exploiting metabolic vulnerabilities in Cancer with a dual-transporter-targeted 2-Deoxyglucose analogue for low-dose, potent antitumor activity
10.1021/jacs.5c18136 · doi-reference
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
10.1007/s00280-012-2045-1 · doi-reference
Deubiquitinase UCH-L1 confers paclitaxel resistance via stabilizing PKM2 to promote glycolysis in triple-negative breast cancer
10.1038/s41419-026-08521-7 · doi-reference
Injectable SF-platform orchestrates GPX4-targeted ferroptosis-autophagy-immunogenic circuit for overcoming oxidative resistance in triple-negative breast cancer
10.7150/thno.116013 · doi-reference
TFCP2L1 suppresses breast cancer progression by promoting ferroptosis through direct and PI3K/AKT-mediated inhibition of GPX4
10.1038/s41420-026-03231-7 · doi-reference
Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition
10.1038/nature24297 · doi-reference
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
10.1038/nature23007 · doi-reference
Metastatic breast cancer cells are vulnerable to fatty acid oxidation inhibition through DDX3-DRP1-mediated mitochondrial plasticity
10.1016/j.redox.2025.103845 · doi-reference
SLC31A1 promotes chemoresistance through inducing CPT1A-mediated fatty acid oxidation in ER-positive breast cancer
10.1016/j.neo.2025.101125 · doi-reference